DQWS: AI 评分 54/100 — AI 分析 (4月 2026)

DSwiss, Inc. is a Malaysian biotech-nutraceutical company that develops and distributes health and beauty products across Asia. The company offers a range of products, including coffee, supplements, skincare, and medical equipment.

Key Facts: AI Score: 54/100 Sector: Consumer Defensive

公司概况

概要：

DSwiss, Inc. is a biotech-nutraceutical company based in Malaysia, focusing on health and beauty products across Asian markets. With a diverse product line from coffee to skincare, DSwiss aims to address consumer needs in digestive health, immunity, and overall well-being, operating in a competitive consumer defensive sector.

DQWS是做什么的？

DSwiss, Inc., incorporated in 2015 and headquartered in Kuala Lumpur, Malaysia, operates as a biotech-nutraceutical company focused on the development and distribution of health and beauty products. The company's product portfolio includes DSwiss coffee, designed to promote digestive health; DSwiss kiwi, which supports the immune system and enhances skin complexion; DSwiss Triple SC, targeting stem cell benefits; and a variety of skincare products like the DSwiss silk mask, coffee slimming scrub, peppermint slimming gel, new age essence, and enlighten essence cream. Beyond nutraceuticals and skincare, DSwiss also offers medical devices and consumables, including DSwiss BioSpec eyewear, Genmune-Pro for immune system support, SkinEra for various skin conditions, SensiBath gel, SuiSu hand and air sanitizers, and MasterLiv, MasterHeart, and WellG supplements targeting liver, heart, and metabolic health, respectively. The company provides diagnostic equipment such as the DSwiss quantum magnetic analyzer and AI skin analyzer machine. Additionally, DSwiss offers medical consumables like surgical gowns, masks, and protective eyewear, along with DNA microarray genotyping services. DSwiss distributes its products across Malaysia, Singapore, Indonesia, Taiwan, Macau, Hong Kong, and China, catering to a wide range of consumer health and beauty needs. The company also offers turnkey private label manufacturing services, expanding its reach within the industry.

DQWS的投资论点是什么？

DSwiss, Inc. presents a speculative investment opportunity within the biotech-nutraceutical sector, characterized by a small market capitalization of $0.01 billion and negative profitability metrics, including a P/E ratio of -152.18 and a profit margin of -1.2%. The company's diverse product range and geographic reach across Asian markets offer potential growth avenues. However, the company's OTC listing and negative beta of -0.72 indicate higher risk and volatility. Key growth catalysts include expanding its product line and penetrating deeper into existing markets. The company's ability to achieve profitability and manage its operational costs will be crucial in determining its long-term success. Investors should carefully consider the risks associated with investing in a small-cap, OTC-listed company with negative profitability.

DQWS在哪个行业运营？

DSwiss, Inc. operates within the consumer defensive sector, specifically in the household and personal products industry. This sector is generally characterized by stable demand, as consumers continue to purchase essential goods regardless of economic conditions. The market is competitive, with established players like BABB (BAB, Baby Banz North America), CAWW (Cawwaii Global), CLGOF (Clearly Canadian Beverage Corporation), EWLU (Euro Waste Logistics), and GGII (Green Globe International, Inc.) competing for market share. DSwiss differentiates itself through its focus on biotech-nutraceutical products and its presence in Asian markets. The industry is influenced by trends such as increasing consumer awareness of health and wellness, growing demand for natural and organic products, and the rise of e-commerce.

Household & Personal Products

Consumer Defensive

DQWS有哪些增长机遇？

Expanding product line with innovative biotech-nutraceutical solutions: DSwiss can capitalize on the growing consumer interest in health and wellness by introducing new products that address specific health needs. The global nutraceuticals market is projected to reach $441.7 billion by 2026, offering a significant opportunity for DSwiss to increase its market share. Timeline: Ongoing.
Deepening market penetration in existing Asian markets: DSwiss can focus on strengthening its distribution channels and marketing efforts in Malaysia, Singapore, Indonesia, Taiwan, Macau, Hong Kong, and China. The rising disposable incomes and increasing health awareness in these markets provide a favorable environment for DSwiss to grow its sales. Timeline: Ongoing.
Leveraging e-commerce platforms to reach a wider customer base: DSwiss can expand its online presence by partnering with e-commerce platforms and developing its own online store. The growth of e-commerce in Asia provides a cost-effective way for DSwiss to reach new customers and increase its brand awareness. The e-commerce market in Southeast Asia is expected to reach $172 billion by 2025. Timeline: Upcoming.
Offering private label manufacturing services to other companies: DSwiss can leverage its manufacturing capabilities to provide private label services to other companies in the health and beauty industry. This can generate additional revenue streams and diversify the company's business model. The private label market is expected to grow at a CAGR of 5.6% from 2021 to 2026. Timeline: Ongoing.
Investing in research and development to create proprietary formulations: DSwiss can differentiate itself from competitors by developing unique and effective formulations for its products. This requires investing in research and development and building a team of experienced scientists and researchers. Proprietary formulations can command higher prices and create a competitive advantage. Timeline: Ongoing.

Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
Negative P/E ratio of -152.18 reflects current unprofitability, requiring investors to focus on future earnings potential.
Gross margin of 16.5% suggests challenges in cost management and pricing strategy.
Negative beta of -0.72 indicates an inverse correlation with the market, potentially offering diversification benefits but also reflecting business-specific risks.
Presence in multiple Asian markets including Malaysia, Singapore, and China, provides geographic diversification and access to growing consumer markets.

DQWS提供哪些产品和服务？

Develops and distributes health and beauty products.
Offers nutraceutical products like DSwiss coffee and DSwiss kiwi.
Provides skincare solutions including masks, scrubs, and essences.
Manufactures medical devices such as BioSpec eyewear and quantum magnetic analyzers.
Supplies medical consumables like surgical gowns and masks.
Offers DNA microarray genotyping services.
Provides private label manufacturing services.

DQWS如何赚钱？

Direct sales of health and beauty products through various distribution channels.
Revenue from medical device and consumable sales.
Income from DNA microarray genotyping services.
Fees from private label manufacturing services.

Individual consumers seeking health and beauty products.
Hospitals and clinics purchasing medical devices and consumables.
Other companies utilizing private label manufacturing services.

Proprietary formulations in nutraceutical and skincare products.
Established distribution network in Asian markets.
Diverse product portfolio catering to various consumer needs.
Manufacturing capabilities for medical devices and consumables.

什么因素可能推动DQWS股价上涨？

Upcoming: Expansion of product line with innovative biotech-nutraceutical solutions to address specific health needs.
Ongoing: Deepening market penetration in existing Asian markets through strengthened distribution and marketing efforts.
Upcoming: Leveraging e-commerce platforms to reach a wider customer base and increase brand awareness.
Ongoing: Offering private label manufacturing services to other companies in the health and beauty industry to generate additional revenue.
Ongoing: Investing in research and development to create proprietary formulations and differentiate from competitors.

DQWS的主要风险是什么？

Potential: Intense competition from established players in the health and beauty industry.
Potential: Fluctuations in currency exchange rates can impact profitability.
Potential: Changes in regulatory requirements in different Asian markets.
Potential: Economic slowdown in key markets can reduce consumer spending.
Ongoing: Negative profitability metrics (P/E, profit margin) indicate financial challenges.

DQWS的核心优势是什么？

Diverse product portfolio in health and beauty.
Presence in multiple Asian markets.
Manufacturing capabilities for medical devices and consumables.
Offers private label manufacturing services.

DQWS的劣势是什么？

Negative profitability metrics (P/E, profit margin).
Small market capitalization.
OTC listing indicates higher risk.
Limited brand recognition compared to larger competitors.

DQWS有哪些机遇？

Expanding product line with innovative solutions.
Deepening market penetration in existing markets.
Leveraging e-commerce platforms for wider reach.
Increasing demand for health and wellness products in Asia.

DQWS面临哪些威胁？

Intense competition from established players.
Fluctuations in currency exchange rates.
Changes in regulatory requirements.
Economic slowdown in key markets.

DQWS的竞争对手是谁？

Baby Banz North America — Focuses on children's protective gear. — (BABB)
Cawwaii Global — Specializes in beauty and personal care products. — (CAWW)
Clearly Canadian Beverage Corporation — Offers premium sparkling water beverages. — (CLGOF)
Euro Waste Logistics — Provides waste management and logistics solutions. — (EWLU)
Green Globe International, Inc. — Focuses on sustainable and eco-friendly products. — (GGII)

Key Metrics

MoonshotScore: 54/100

Company Profile

CEO: Ming Chia Leong
Headquarters: Kuala Lumpur, MY
Employees: 13
Founded: 2017

AI Insight

AI analysis pending for DQWS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does DSwiss, Inc. do?

DSwiss, Inc. is a biotech-nutraceutical company that develops, manufactures, and distributes a range of health and beauty products across several Asian markets, including Malaysia, Singapore, and China. Their product line includes nutraceuticals like DSwiss coffee and kiwi, skincare products, medical devices such as BioSpec eyewear, and medical consumables like surgical masks. The company also provides private label manufacturing services, catering to other businesses in the health and beauty sector. DSwiss aims to address consumer needs in digestive health, immunity, and overall well-being through its diverse offerings.

What do analysts say about DQWS stock?

AI analysis is currently pending for DQWS. Due to its OTC listing and small market capitalization, there is limited analyst coverage available. Key valuation metrics such as the negative P/E ratio (-152.18) and low gross margin (16.5%) suggest that the company is currently unprofitable. Growth considerations include expanding its product line, penetrating deeper into existing markets, and leveraging e-commerce platforms. Investors should conduct thorough due diligence and consider the risks associated with investing in a small-cap, OTC-listed company with limited financial information.

What are the main risks for DQWS?

The main risks for DSwiss, Inc. include intense competition from established players in the health and beauty industry, fluctuations in currency exchange rates, and changes in regulatory requirements in different Asian markets. Additionally, the company faces risks associated with its OTC listing, such as limited financial disclosure, low trading volume, and potential for price volatility. The negative profitability metrics (P/E, profit margin) also indicate financial challenges. Investors should carefully consider these risks before investing in DQWS.